Compare VRAX & NUWE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRAX | NUWE |
|---|---|---|
| Founded | 2013 | 1999 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8M | 2.9M |
| IPO Year | 2022 | N/A |
| Metric | VRAX | NUWE |
|---|---|---|
| Price | $0.66 | $2.34 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $3.00 | N/A |
| AVG Volume (30 Days) | ★ 14.7M | 48.2K |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $2,986.00 | ★ $8,167,999.00 |
| Revenue This Year | $217,274.83 | N/A |
| Revenue Next Year | N/A | $10.48 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.35 | $2.02 |
| 52 Week High | $3.20 | $70.14 |
| Indicator | VRAX | NUWE |
|---|---|---|
| Relative Strength Index (RSI) | 69.02 | 42.18 |
| Support Level | $0.39 | $2.24 |
| Resistance Level | $0.43 | $2.55 |
| Average True Range (ATR) | 0.06 | 0.19 |
| MACD | 0.02 | 0.04 |
| Stochastic Oscillator | 55.35 | 46.72 |
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes (HSV-1) and Human Papillomavirus (HPV).
Nuwellis Inc is a medical technology company focused on developing, manufacturing, and commercializing a medical device used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems. The Aquadex Smartflow System removes excess fluid from patients suffering from fluid overload who have not responded to medical management, including diuretics. Nuwellis has one reportable segment: fluid overload.